Fuad Naser

Fuad Naser, PhD, is an Analyst at RA Capital Management, a leading investment firm based in Boston, MA, where he actively contributes to both public and private market investments. In his current role on the investment team, Dr. Naser is focused on identifying, evaluating, and supporting innovative healthcare and life sciences companies, working across the biotechnology and medical device sectors.

Prior to his appointment as Analyst, Dr. Naser advanced through roles of Senior Associate and Associate at RA Capital, evidencing his diligence and expertise in investment analysis since joining the firm in 2021. His responsibilities have included serving as a Board Observer at companies such as Ceribell and Exo, furthering his leadership and sector-specific insight in point-of-care diagnostics and medical technologies.

Dr. Naser earned his Doctor of Philosophy (Ph.D.) in Biological Chemistry and a Bachelor’s degree in Biochemistry and Molecular Biology, both from Washington University in St. Louis, equipping him with a rigorous scientific foundation to navigate complex areas of the life sciences industry. Recognized for his detailed sector coverage and scientific acumen, he has become a valued contributor to investment diligence and firm-wide thought leadership in biotech and healthcare innovation.